The Chicago Protocol The rain in Chicago doesn't fall. It hangs in the air like a curtain, gray and persistent, and if you stand still long enough it finds its way into your bones. I learned this in '43, in the trenches outside Bastogne, where the rain mixed with mud and blood and became something you couldn't wash off no matter how hard you scrubbed. I learned it again in '47, in this city, where the rain mixed with soot and river water and became something that stained everything it touched. My name is Frank Keller. I'm twenty-five years old. I survived the war. And I am completely, utterly screwed. It started with the pills. Blue capsules, imprinted with the letters T-R-A-C, standing for TheraCalm, the new tranquilizer that every doctor in Chicago was prescribing for everything from insomnia to nervous breakdowns to what my grandmother used to call "the fidgets." I was an intern at Lincoln Park Public Hospital, which is a fancy way of saying it was a hospital for people who couldn't pay and nobody cared about. My attending was Dr. Harold Winslow, a man of fifty-five with a silver mustache and a handshake that felt like a contract you hadn't read carefully enough. "Mr. Keller," he said on my first day, "you're a Korean War veteran. That means you understand discipline. This hospital runs on discipline. You follow orders, you keep your head down, and you don't ask questions about things that don't concern you." I nodded. I'd heard this before. TheraCalm became a concern three weeks later, when Patient 14-B died. Her name was Eleanor Voss, a sixty-two-year-old widow who had been admitted for anxiety and insomnia. Winslow had prescribed TheraCalm, two capsules at bedtime. On the third night, she developed severe tremors. By morning, she was unresponsive. By evening, she was dead. The official cause of death: cardiac arrest. I reviewed her chart in the records room, alone, after hours. Cardiac arrest didn't explain the tremors. Cardiac arrest didn't explain the dilated pupils. Cardiac arrest didn't explain the strange blue tint to her fingernails that I had noticed when I checked her pulse that morning. I pulled the medication logs. Eleanor Voss had received seventeen doses of TheraCalm over ten days. I cross-referenced this with the hospital's adverse event reports—a document so poorly maintained it consisted of three pages of blank forms and one handwritten note from 1943 that read "calm patients = happy donors." There were seventeen other patients on the TheraCalm log who had experienced neurological side effects. Seventeen. And zero adverse event reports. I went to Winslow. "Doctor, I reviewed Patient 14-B's chart. The cause of death doesn't match the symptoms. And there are seventeen other patients on TheraCalm who've had neurological reactions. I think we need to— " Winslow looked up from his desk. He was a handsome man, in a cold, sculpted way, like a statue of a Roman emperor that had been left out in the rain too long. "Mr. Keller," he said, "you are an intern. You are paid to treat patients, to write charts, and to shut your mouth when something is above your pay grade. Do you understand?" "I think there's something wrong with TheraCalm." Winslow stood. He was taller than I remembered. "Mr. Keller, this hospital receives fifty thousand dollars a year from American Pharmaceutical Group in exchange for our cooperation in clinical trials. TheraCalm is part of those trials. If you have a problem with that, you can take it up with the Board of Governors. But I assure you, they will not be sympathetic." I left his office and went to the bathroom and splashed cold water on my face and stared at myself in the mirror and didn't recognize the man looking back. I started keeping a secret log. Not in the hospital records—those were monitored. In a small notebook that I kept in my locker, behind a stack of old gauze pads. Patient name. Date of admission. TheraCalm dosage. Side effects. Progression. The pattern was clear. Of the forty-two patients I tracked who received TheraCalm for more than two weeks, eleven developed neurological symptoms. Four developed irreversible brain damage. One died. I made copies of the key pages. Not photocopies—the hospital didn't have a machine that good. I copied them by hand, in my cramped physician's handwriting, in a notebook that looked like nothing more than a doctor's personal notes. I took the notebook to a woman named Erin Donovan. Erin was a reporter for the Chicago Tribune, an investigative journalist with a reputation for making powerful men uncomfortable. We had met at a bar on State Street six months earlier, when I was nursing a whiskey and she was nursing the same whiskey and asking me questions about my war service that I wasn't ready to answer. We had been seeing each other since. She was sharp and beautiful and dangerous, and I loved her for all three reasons. "Frank," she said, reading the notebook in her apartment on a Sunday morning, the Chicago sun trying valiantly to break through the clouds and failing. "This is huge." "I know." "American Pharmaceutical Group is one of the largest companies in the country. Their stock has tripled in the past two years. TheraCalm is their flagship product." "I know." "Who else knows?" "No one." She looked at me for a long time. "You realize what happens if you publish this." "I realize a lot of things." "Do you?" "Yes." We set the publication for Thursday. Erin needed the week to verify the data, to find independent medical experts who could confirm the neurological damage was caused by TheraCalm and not by pre-existing conditions. Thursday morning, the story would run on the front page. On Wednesday night, I came home from the hospital at midnight. My apartment was on the third floor of a building on South Halsted Street. I climbed the stairs, turned the key in the lock, and stopped. Something was wrong. The apartment had been searched. Not ransacked—searched. Everything was in its place, except for the things that mattered. My locker key was gone. My notebook was gone. My wallet was on the table, open, with fifty dollars missing. But the fifty dollars wasn't the point. The point was the single blue TheraCalm capsule sitting in the center of my kitchen table, like a offering or a threat. I called Erin. She didn't answer. I called again. No answer. I drove to her apartment in the rain, my hands white-knuckled on the steering wheel, the wipers slapping back and forth in a rhythm that reminded me of artillery fire. Her building was dark. Her door was locked. I knocked for ten minutes. No answer. Her landlord came down in his pajamas. "Miss Donovan? She left this morning. Early. Said she had an assignment." "Where did she go?" "Chicago Tribune. Probably." I drove to the Tribune building. The front desk clerk said Erin had come in Wednesday morning, looked at the page proofs for the TheraCalm story, and then left without a word. She had not returned. On Friday morning, Winslow called me into his office. "Mr. Keller, I understand you've been conducting unauthorized research on TheraCalm." "I don't know what you're talking about." Winslow opened a drawer and slid a piece of paper across the desk. It was a copy of my notebook. Every page. Every word. "Mr. Keller, I want to be very clear with you. American Pharmaceutical Group has decided to withdraw their clinical trial agreement with this hospital. That means fifty thousand dollars a year disappears. The new wing you helped fund? Funded by that money. Disappears." "I tried to warn you." "You interfered with a business relationship. And you endangered the financial stability of this institution." Winslow leaned forward. "I have access to your military records, Mr. Keller. I know about the nightmares. I know about the medication you were prescribed for combat stress. And I know that a diagnosis of combat stress reaction can be grounds for revoking a medical license." I felt the room tilt slightly. Not dramatically. Just enough to know that the floor was no longer level. "What are you saying?" "I'm saying that starting today, you are relieved of your internship duties. I'm also saying that if you attempt to publish whatever fantasy you've constructed about TheraCalm, I will personally ensure that you never practice medicine in this state again. Do we understand each other?" "Yes." "Good." I left Chicago on a Tuesday in November. I drove west in my Ford, the rain following me the entire way, blurring the road until I couldn't tell where the pavement ended and the darkness began. I stopped in Detroit at a bar called The Blue Note and took a job as a night receptionist. The pay was twelve dollars a week, room and board included. It was enough. I don't know what happened to Erin Donovan. I don't know if her story was ever published. I don't know if TheraCalm is still being prescribed. I know this: six months after I left Chicago, TheraCalm was approved for nationwide distribution by the FDA. The company's stock doubled. I know this too: every night, before I go to sleep, I take a sleeping pill. Not TheraCalm. Something older. Something safer. But sometimes, in the dark, when the bar is quiet and the rain is falling on the Detroit river, I close my eyes and I see Eleanor Voss's fingernails, blue in the dim light of the hospital ward, and I wonder if anyone ever knew her name. The rain in Chicago doesn't fall. It hangs in the air like a curtain. And if you stand still long enough, it finds its way into your bones. E_total: 31.7 | Dominant Mode: M1(Tragedy) | Style: Film Noir © 2026 - Authored by Z R ZHANG ( EL9507135 -- デスプアトカザスピカツ[⾙、のくる] Dд;由需史 Роусетиме ѣђєАџГНЬмЩцебесЬн Passnummer ترجاجسسسف CHN Passport) The aforementioned Author hereby grants to OXFORD INDUSTRIAL HOLDING GROUP (ASIA PACIFIC) CO., LIMITED （BRN74685111） all economic property rights, including but not limited to the rights of: reproduction, distribution, rental, exhibition, performance, communication to the public via information network, adaptation, compilation, commercial operation, authorization for third-party use, and rights enforcement. Such grant is exclusive and irrevocable. The term of such rights shall be 49 years from the date of publication. To contact author, please email to datatorent@yeah.net